Organisation paid for research Program year 2025 Source: CMS Open Payments

Peritus Imaging Inc

Neither a doctor nor a teaching hospital

Research payments

$2,468,139

620 payments

Through program year 2025, Peritus Imaging Inc is reported as receiving $2,468,139 in research payments, across 620 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$90,835	35
2024	Research	$135,864	58
2023	Research	$139,491	80
2022	Research	$205,452	76
2021	Research	$761,345	145
2020	Research	$659,150	141
2019	Research	$476,002	85

Breakdown

Who paid Research payments · program years 2019–2025

Acerta Pharma LLC $813,051 15 payments
AbbVie, Inc. $312,155 334 payments
Hoffmann-La Roche Limited $283,870 17 payments
AstraZeneca UK Limited $238,643 8 payments
Pharmacyclics LLC, An AbbVie Company $233,800 58 payments
Roche Products Limited $167,810 12 payments
EMD Serono, Inc. $124,220 34 payments
GlaxoSmithKline, LLC. $102,710 34 payments
TESARO, Inc. $46,810 8 payments
BeiGene, Ltd. $42,310 24 payments

Studies the money was for Research payments · program years 2019–2025

A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma $714,659 15 payments
A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia $268,045 3 payments
Phase III Ipatasertib Plus Abirateron in McRpc 1St Line $255,765 9 payments
Phase III Study in Adjuvant Therapy in Renal Cell Carcinoma Patients $167,810 12 payments
A Phase 1 Dose Escalation and Cohort Expansion Study of Tsr-042, An An $79,375 24 payments
Emr 100070-005 $72,680 8 payments
A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of recurrent or Stage IV PD-L1+ non small cell lung cancer $49,940 25 payments
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) $48,015 12 payments
Pcyc-1142-Ca $47,445 14 payments
A Phase 1 Dose Escalation and Cohort Expansion Study of Tsr-042, An Anti-Pd-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors $46,810 8 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.